Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00346814
Verified June 2006 by Asociación para Evitar la Ceguera en México. Recruitment status was: Recruiting
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
1 Month to 12 Months (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY
PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER